Clinical practice in atrial fibrillation (AF) patient management is constantly evolving. In the
past 3 years, various new AF guidelines or focused updates have been published, given this …

It is well established that direct oral anticoagulants (DOACs) are the cornerstone of
anticoagulant strategy in atrial fibrillation (AF) and venous thromboembolism (VTE) and …

Aims Persistence with direct oral anticoagulants (DOACs) has become a concern in non-
valvular atrial fibrillation (NVAF) patients, but whether this affects prognosis is rarely studied …

Stroke prevention is a key clinical concern in the management of patients with atrial
fibrillation. Oral anticoagulation treatment reduces the risk of disabling stroke, but the …

Objective To describe patterns of anticoagulation prescription and persistence for those
aged≥ 65 years with atrial fibrillation (AF). Methods Descriptive cohort study using …

Low socioeconomic status has been associated with poor outcomes in patients with atrial
fibrillation (AF). However, little is known about socioeconomic disparities in adherence to …

Introduction Oral anticoagulants (OACs) prevent stroke in patients with atrial fibrillation (AF).
Several factors may cause OAC switching. Objectives To examine the phenomenon of OAC …

Background Many patients who used vitamin K antagonists (VKAs) for longterm prevention
of thromboembolism are now actively switched to a direct oral anticoagulant (DOAC). Strict …

Background In January 2021, the Dutch vaccination program against severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) was started. Clinical studies have shown …

Aims: To describe and compare the adherence to different direct oral anticoagulants
(DOACs) in eight European databases representing six countries. Methods: Longitudinal …